Hughes

Hughes Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for metabolic diseases and oncology. The company's primary research efforts are directed toward addressing high-unmet-need conditions such as non-alcoholic steatohepatitis (NASH) and type 2 diabetes through multi-target mechanisms. Their lead candidate, HBT-1702, is a potent farnesoid X receptor (FXR) agonist designed to treat liver fibrosis and metabolic dysfunction. Hughes Biotechnology leverages its expertise in medicinal chemistry to create optimized compounds with improved safety and efficacy profiles compared to existing standards of care.